Previous 10 | Next 10 |
NRx Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update PR Newswire Four near-term milestones, including initiation of potential spinout initiatives expected in 2023/early 2024 Completing enrollment of the originally-targeted...
NRx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 14, 2023 PR Newswire RADNOR, Pa. , Nov. 7, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a late-stage biopharmaceutical company,...
NRx Pharmaceuticals Announces Signing of a Development Agreement for the Manufacture of Ketamine to Treat Suicidality and Depression PR Newswire FDA-compliant manufacture of intravenous Ketamine is a required component of a New Drug Application Intravenous Ketamine h...
NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain PR Newswire "Study May Proceed" letter received from FDA IND preclinical requirements are consistent with studies already in p...
NRx Pharmaceuticals Announces Strategic Change in Development of NRX-100 (IV Ketamine) at Dawson James Small Cap Investor Conference PR Newswire Previously announced data sharing agreement for intravenous ketamine Newly available data highlight the need for a labeled...
NRx Pharmaceuticals to Present at 8th Annual Dawson James Conference PR Newswire RADNOR, Pa. , Oct. 5, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announce...
NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic Pain PR Newswire Allows initiation of the NRX-101 commercial development to treat Chronic Pain Company plans to seek Fast Track and Brea...
JUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8 th Annual Dawson James Small Cap Growth Conferen...
NRx Pharmaceuticals Publishes Shareholder Update Letter PR Newswire Focus on implications of the recent Data Sharing Agreement relating to a landmark trial of Ketamine in the treatment of Suicidal Depression NMDA antagonist highly effective in Bipolar subgroup (p<...
NRx Pharmaceuticals to Present at the Sidoti Virtual Small Cap Conference PR Newswire RADNOR, Pa. , Sept. 18, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today a...
News, Short Squeeze, Breakout and More Instantly...
NRX Pharmaceuticals Inc. Company Name:
NRXP Stock Symbol:
NASDAQ Market:
NRX Pharmaceuticals Inc. Website:
NRx Pharmaceuticals (NASDAQ:NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing PR Newswire New Drug Application (NDA) for Accelerated Approval planned for NRX-101 in people with bipolar depression and akathisia in 202...
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024 PR Newswire RADNOR, Pa. , June 20, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"...
NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors PR Newswire Dr. Dennis McBride brings extensive experience in Neuroscience and its interface with Information and Medical Technology ...